Phio Pharmaceuticals Corp. (PHIO) Stock Price & Analysis
Phio Pharmaceuticals Corp. (PHIO) fell 0.92% to USD 1.08 as of June 10, 2026 at 03:13 UTC, according to Nexqual real-time market data.
PHIO last closed at USD 1.09; the session ranged USD 1.07–1.13 on volume of 175,148 shares. Market capitalization is $12.55M, with a 52-week range of USD 0.81–4.19 (NCM). Source: Nexqual, June 10, 2026 at 03:13 UTC.
Key Statistics (as of June 10, 2026 at 03:13 UTC)
| Price | USD 1.08 |
|---|---|
| Change | ▼ 0.92% (down) |
| Previous Close | USD 1.09 |
| Open | USD 1.09 |
| Day Range | USD 1.07 – 1.13 |
| 52-Week Range | USD 0.81 – 4.19 |
| Volume | 175,148 shares |
| Market Cap | $12.55M |
| Exchange | NCM |
Technical Analysis (PHIO)
Nexqual's technical model rates PHIO "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:13 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 42 (neutral) |
| vs SMA50 | Below (USD 1.17) |
| MACD | -0.02 (negative) |
Analyst Ratings (PHIO)
Wall Street analysts rate PHIO "None" based on 1 analysts, with a mean price target of USD 14 (range USD 14–14), per Nexqual as of June 10, 2026 at 03:13 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 14 |
| High Target | USD 14 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (PHIO)
| EPS Estimate | USD -0.36 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.34 vs est -0.24 ▼ miss |
| 2025-12-31 | USD -0.15 vs est -0.47 ▲ beat |
| 2025-09-30 | USD -0.44 vs est -0.44 ▲ beat |
| 2025-06-30 | USD -0.45 vs est -0.36 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financials & Fundamentals (PHIO)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -76.36% |
| Current Ratio | 18.32 |
| Total Cash | $17.03M |
| Total Debt | $0 |
| Free Cash Flow | $-7.25M |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Financial Health Score (PHIO)
Nexqual rates Phio Pharmaceuticals Corp.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:13 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $17M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$11M |
| Efficiency | Critical — ROE -76%, ROA -46.7% |
Ownership (PHIO)
| Insider Ownership | +6.00% |
|---|---|
| Institutional Ownership | +10.82% |
| Shares Outstanding | 11.62M |
| Float | 11.55M |
| Short % of Float | +2.71% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
Leadership (PHIO)
Phio Pharmaceuticals Corp. is led by Robert J. Bitterman (age 74), President, CEO & Chairman, per Nexqual as of June 10, 2026 at 03:13 UTC.
| President, CEO & Chairman | Robert J. Bitterman (age 74) |
|---|---|
| CFO, Principal Accounting Officer and VP of Finance & Administration | Lisa C. Carson (age 58) |
| Senior Vice President of Development | Linda M. Mahoney |
| Senior Vice President of Regulatory & Corporate Affairs | Jennifer Phillips Pharm.D. |
Major Backers & Investors (PHIO)
Notable institutional backers of Phio Pharmaceuticals Corp. include Fidelity, Jane Street Group, LLC, Delaware Group Equity Funds IV-Nomura Healthcare Fund, according to Nexqual as of June 10, 2026 at 03:13 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fidelity | 1.05% |
| Jane Street Group, LLC | 1.03% |
| Delaware Group Equity Funds IV-Nomura Healthcare Fund | 0.43% |
| Cetera Investment Advisers | 0.39% |
| HRT Financial LP | 0.3% |
| Two Sigma Investments, LP | 0.28% |
| Scientech Research LLC | 0.26% |
| UBS Group AG | 0.23% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.71% |
| Geode Capital | 1.27% |
Source: Nexqual, June 10, 2026 at 03:13 UTC.
From Phio Pharmaceuticals Corp.'s Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States.
- It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.11 | ▼ 2.63% |
| RKTO | Rocket One Inc. | USD 1.28 | ▼ 15.23% |
| PSTV | PLUS THERAPEUTICS, Inc. | USD 5.5 | ▲ 1.66% |
| DCOY | Decoy Therapeutics Inc. | USD 5.51 | ▼ 16.64% |
| ADTX | Aditxt, Inc. | USD 0.03 | ▼ 53.39% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:13 UTC. This page is informational and not investment advice.